Hayley Virgil

First-Line Opdivo-Novel Therapy Combo More Than Doubles Survival in Advanced Skin Cancer

May 20, 2021

The use of Opdivo combined with the novel therapy relatlimab resulted in a significant improvement of progression-free survival compared to treatment with Opdivo, alone, in patients with previously untreated, unresectable or metastatic melanoma.